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Abstract: Prostate cancer is the second most common lethal cancer in men worldwide. Despite the fact that the 
prognosis for patients with localized disease is good, many patients succumb to metastatic disease with the 
development of resistance to hormone treatments. This is normally termed castration-resistant prostate cancer (CRPC). 
The development of metastatic, castration-resistant prostate cancer has been associated with epithelial-to-mesenchymal 
transition (EMT), a process where cancer cells acquire a more mesenchymal phenotype with enhanced migratory 
potential, invasiveness and elevated resistance to apoptosis. The main event in EMT is the repression of epithelial 
markers such as E-cadherin and upregulation of mesenchymal markers such as N-cadherin, vimentin and fibronectin. 
The insulin-like growth factor (IGF) signalling axis is essential for normal development and maintenance of tissues, 
including that of the prostate, and dysregulation of this pathway contributes to prostate cancer progression and 
malignant transformation. It is becoming increasingly clear that one of the ways in which the IGF axis impacts upon 
cancer progression is through promoting EMT. This review will explore the role of EMT in prostate cancer progression 
with a specific focus on the involvement of the IGF axis and its downstream signalling pathways in regulating EMT in 
prostate cancer. 
Keywords: Epithelial-to-mesenchymal transition, insulin-like growth factor family, prostate cancer progression, 
lifestyle factors. 
PROSTATE CANCER 
Prostate cancer is the second most common lethal 
cancer diagnosed in men. According to The American 
Cancer Society, it is estimated that more than 220 000 
new cases of prostate cancer will occur in the United 
States during 2015 accounting for about 26% of all 
cancers in men with a mortality rate of 9%: the second 
highest cause of cancer deaths in men after lung 
cancer [1].  
Age is the biggest risk factor for PCa with the 
incidence of prostate cancer being higher in older men 
particularly in men aged 65 and above [2]. The 
incidence of, and mortality from, prostate cancer varies 
hugely within different racial and ethnic groups. Much 
higher incidence and death rates are reported in black 
men compared to other races [3,4]: the reasons 
underlying these observations are still unclear but both 
genetic and/or environmental influences may be 
involved. A number of epidemiology studies have also 
reported that family history is a risk factor for PCa- with 
approximately 5-10% of cases being attributable to 
inherited genetic factors or PCa susceptibility genes 
[5,6].  
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The prognosis for patients with localized disease is 
good, however the morbidity and mortality for prostate 
cancer patients who develop metastatic disease is high 
[7]. Androgen deprivation therapy (ADT) which involves 
surgical or chemical castration plays an important role 
in the treatment and management of prostate cancer 
and is also utilised as an adjuvant or neo-adjuvant 
treatment for high-risk disease [8]. The response to the 
treatments is however temporary and the patient often 
undergoes disease recurrence and metastasis and 
inevitability progresses to castration-resistance 
prostate cancer (CRPC) [9]. An epidemiology study 
conducted on 2494 non-metastatic prostate cancer 
patients undergoing ADT showed that within five years, 
80% of the patients developed CRPC and nearly 25% 
developed metastases, with the majority having bone 
metastases [10]. Metastatic prostate cancer particularly 
bone metastases have been regarded as a lethal form 
of prostate cancer and remains an incurable disease at 
present since current therapy can only delay the 
progression of the cancer [11,12]. 
The extensive use of prostate-specific antigen 
(PSA) testing has dramatically changed the prostate 
cancer landscape, enhancing prostate cancer detection 
at an earlier stage for which immediate treatment can 
be given [7]: screening has led to a large increase in 
the number of detected prostate cancers. The major 
issue in the clinical management of prostate cancer is 
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that there is no way to accurately determine at the time 
of diagnosis which cancers will develop into a lethal 
disease from those cancers that will not impact on a 
man’s life. Consequently, almost all men with PSA-
detected cancer, which has increased due to 
screening, opt for treatment, even though for the 
majority it is probably not required.  
This has led to many researchers focusing on other 
contributory factors that could be important in 
determining whether a cancer progresses to a life-
threatening disease including environmental 
exposures, endogenous hormones and the complex 
interactions between these influences [4,13]. 
Epidemiology studies have contributed greatly to our 
understanding of the impact of the environment in the 
pathogenesis of prostate cancer as well as other 
epithelial cancers. This has been convincingly 
demonstrated by migrant studies: migrants from Asia 
who move to Western countries develop a higher 
prevalence of prostate cancer compared with the native 
Asian populations and adopt the cancer risk of the host 
population within a couple of generations [14]. Such 
evidence clearly indicates that the development of 
clinically aggressive cancers in migrants cannot be due 
to genetic mutations over this short period of time but 
must be heavily influenced by an altered lifestyle and 
different environmental exposures. A western lifestyle 
or western diet is characterised by physical inactivity 
accompanied with excessive intake of processed 
foods, red meat, dietary fat, refined carbohydrates, or 
excess calories [15]. As prostate cancer is detected in 
older men they often also present with co-morbities 
including obesity, hyperinsulinemia, and insulin 
resistance. Recent studies have shown an association 
between metabolic syndrome and an increased risk of 
prostate cancer progression to advanced disease and 
prostate cancer-specific mortality [16,17]. A meta-
analysis on the association between diabetes and PCa 
showed that diabetic patients had a reduced risk of 
developing PCa [18]. However, despite the risk of 
developing PCa being reduced by diabetes, [19] men 
having both prostate cancer and diabetes, suffered 
more aggressive tumours, a higher risk of cancer 
recurrence and worse overall survival [20] which 
suggests metabolic exposures affect progression but 
not initiation, consistent with the epidemiology 
observations of geographical variations. 
The crucial underlying molecular mechanism that 
promotes the progression of localised prostate cancer 
to become metastatic and castration resistant remains 
largely elusive. Contributing mechanisms have been 
suggested for development of metastatic androgen-
independent prostate cancer including androgen 
receptor (AR) over-expression, AR splice variants such 
as AR3/AR-V7 and AR4/AR-V1, and mutations in the 
ligand binding domain of the AR as well as cross-talk 
with other growth factor signalling pathways particularly 
the insulin-like growth factor (IGF) axis [21]. But still, 
targeted therapy to the AR signalling axis for treatment 
of castration resistant prostate cancer has yet to be 
fully effective.  
INSULIN-LIKE GROWTH FACTOR (IGF) AXIS  
The IGF system comprises two ligands (IGF-I and 
IGF-II); three receptors: IGF-I receptor (IGF-IR), insulin 
receptor (IR) and the IGF-II/mannose-6-phosphate 
receptor (IGF-IIR) and a family of six high-affinity IGF 
binding proteins (IGFBP-1 to -6) (see Figure 1). 
Together they are involved in multiple signalling 
pathways that promote cell proliferation, differentiation, 
migration and survival. Both IGF-I and –II are 
multifunctional regulatory peptides and have similar 
structural homology with proinsulin [22, 23]. The 
synthesis of IGF-I, IGF-II, and insulin is regulated by 
diverse mechanisms with the major regulators being 
nutrient intake and growth hormone [24]. Unlike insulin 
and other peptide hormones, IGFs are not synthesized 
and stored within specialized cells in a given tissue. 
Instead, they are ubiquitously produced and released 
by virtually every tissue [25]. IGFs exert their effect by 
predominantly binding to the IGF-IR that exhibits 
structural homology to the IR [26] especially in the 
intracellular tyrosine kinase domain. IGF-IR and IGF-
IIR have different structures and functions. The IGF-IR 
is composed of two identical ?-subunit and two 
identical ?-subunit linked by disulfide bonds [27] 
whereas the IGF-IIR is a single, transmembrane 
structure that is thought to act as a clearance receptor 
for IGF-II [28]. Differential splicing of the IR gene 
produces two isoforms of IR, IR-A and IR-B. IGFs, 
particularly IGF-II has high affinity for IR-A compared to 
its affinity for IR-B. Insulin on the other hand binds with 
similar affinity to both isoforms. IR-B is thought to 
mediate the metabolic response of insulin such as 
glucose uptake [29] whereas IR-A is considered to play 
more of a role in cell growth, proliferation and survival 
[30]. IR-A is the predominant isoform expressed in 
many cancer cells consistent with the increased risk of 
developing cancer in patients with hyperinsulinemia/ 
hyperglycaemia, such as those with concomitant 
obesity and type 2 diabetes [31].  
The interaction between the IGFs and their receptor 
is modulated by IGF-binding proteins (IGFBPs). The 
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IGFBP family consists of six circulating proteins that 
bind with high affinity to the IGFs. They have multiple 
and complex functions in which they exert their action 
dependent or independent of IGF binding. IGFBP 
association with IGFs may either enhance or inhibit 
their actions which results in different outcomes on 
cellular functions. For example, binding of IGFBPs with 
IGFs can hinder the interaction between IGFs and IGF-
IR as the IGFBPs have a higher affinity for the IGFs 
than the receptors which results in suppression of IGF 
actions [32]. Circulating IGFs are almost entirely bound 
to the IGFBPs. IGF binding to its binding protein 
protects the IGF from proteolytic degradation resulting 
in increased bioavailability of circulating IGFs. In 
addition to their role in regulating the bioavailability of 
circulating IGF, it has become clear that IGFBPs can 
also exert effects on numerous cell functions, including 
proliferation, survival, gene transcription and the 
initiation of apoptosis [33–36](see review Baxter, R 
2014) [37].  
EPITHELIAL TO MESENCHYMAL TRANSITION  
Epithelial-to-mesenchymal transition (EMT) is a 
coordinated and organized process that is important 
during development. During this process epithelial cells 
lose their epithelial properties and acquire 
mesenchymal, fibroblast-like characteristics [38]. EMT 
begins when E-cadherin, a calcium dependent cell-cell 
adhesion molecule that mediates epithelial connections 
to neighbouring cells and the basement membrane, is 
down-regulated [39,40]. Apart from loss of E-cadherin 
another critical molecular feature of EMT is repression 
of other cell adhesion proteins including occludin and 
plakoglobin and decreased expression of keratin 
intermediate filaments such as cytokeratin; as well as 
decreased in desmosomes such as desmoplakin 
resulting in dismantling of adherens junctions, 
reorganization of cytoskeletal and subsequent loss in 
cell polarity. The loss in these molecules is 
accompanied by increases in mesenchymal markers 
comprising N-cadherin, vimentin as well as 
 
Figure 1: The Insulin-like growth factor (IGF) system.  
The IGF system consists of the receptors (IR, IGF-IR, IGF-IR/IR hybrids and IGF-IIR), the ligands (IGF-I, IGF-II and insulin), six 
high affinity IGFBPs (-1 to -6) and IGFBP proteases. IGF ligands bind to IGFBPs in the circulation. Binding of an IGF ligand to 
its receptor activates downstream mitogenic and metabolic signalling that regulates cell survival, growth, differentiation and 
metabolism.  
Abbreviations: IGF: insulin-like growth factor; IGFBP: insulin-like growth factor–binding protein; IR: insulin receptor. 
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extracellular matrix molecules such as fibronectin. The 
acquisition of a mesenchymal phenotype leads to 
increases in migratory capacity and invasiveness of the 
cells undergoing EMT [38]. The reduced expression of 
E-cadherin and increased expression of N-cadherin 
has been termed as the “cadherin switch” and is 
proposed as a crucial process in cancer progression 
[39,41]. Another epithelial marker ?-catenin acts to link 
the cytoplasmic domain of E-cadherin to ?-catenin and 
connects the adhesion complex to the actin skeleton 
[42]. In addition, ?-catenin also participates in signal 
transduction through the Wnt signalling pathway. 
Contrary to the non-invasive cells where ?-catenin is 
localised at the membrane, for invasive cells that have 
undergone EMT loss of E-cadherin releases ?-catenin 
into the cytoplasm and the nucleus [43]. Furthermore 
activation of the Wnt pathway also mediates ?-catenin 
nuclear translocation where it associates with 
transcription factors from the T-Cell Factor (TCF)/ 
lymphoid enhancing factor (LEF) family and drives 
transcription of Wnt/? catenin target genes such as 
MYC, inhibitor of differentiation 2 (ID2), achaete-scute 
like 2 (ASCL2), matrix metalloproteinase 7 and 14 
(MMP7 and MMP14) that are known to regulate 
different cellular processes including proliferation, 
differentiation, migration, invasion, survival and 
angiogenesis [44]. During EMT, epithelial cells also 
become resistant to both stress-induced cell death and 
that provoked by pro-apoptotic signals that activate the 
death receptor pathway such as tumour necrosis factor 
? (TNF-?) [45]. This increase in cell survival is triggered 
by the Snail zinc-finger transcription factor by 
suppressing apoptosis and provides a selective 
advantage to invasive cells to migrate and colonize 
distant sites [45].  
EMT AND PROSTATE CANCER PROGRESSION 
Despite the importance of the EMT program during 
embryogenic development, such as during formation of 
the mesoderm and neural crest and throughout life 
during wound healing, emerging evidence suggests 
that the atypical activation of the EMT program, 
attributed to a response to microenvironmental 
alterations and aberrant stimuli, may contribute to 
various pathologic conditions including tissue fibrosis 
and cancer progression [46]. The activation of this 
program in epithelial cancers provides the tumour cells 
with increased migratory and invasive capacity and the 
ability to metastasise. Unwarranted increases in 
epithelial cell proliferation and angiogenesis have been 
regarded as an important step occurring during the 
initiation and early growth of primary epithelial cancers 
followed by the invasion-metastasis cascade, where 
the epithelial cancer cells switch from a collective 
invasion form towards a detached and disseminated 
cell migration mechanism [47]. These changes occur 
through the loss of the cell-cell adhesion complex 
attributed to mutations or loss in cadherin or catenins, 
or from the increase in cadherin cleavage resulting in 
the cancer cells losing their polarity and detaching from 
the basement membrane [47–49]. The acquisition of 
this malignant phenotype by epithelial cancer cells, 
facilitated by the EMT program [48], allows the tumour 
cells to leave the primary tumour site and invade 
through the basement membrane and surrounding 
tissues. Intra-vasation of the cells into a lymphatic or 
blood vessel then occurs, thereby entering the 
systemic circulation. The cells are then transported in 
the vasculature and invade the vascular basement 
membrane and extracellular matrix at secondary sites 
in the process of extravasation. Ultimately these cells 
will attach at the distant organ forming micro-
metastases with the potential to proliferate into fully 
malignant, secondary tumours. The final step in 
metastasis called colonization requires the reversion of 
EMT and/or activation of the mesenchymal to epithelial 
transition (MET) program [48,50] (see Figure 2).  
As mentioned previously, loss of E-cadherin is the 
defining feature of EMT and is of crucial importance in 
cancer invasion and metastasis. The loss of this 
adhesion molecule is accompanied by increases in 
other mesenchymal markers such as N-cadherin, 
vimentin and fibronectin [51]. An increasing number of 
studies demonstrate that in many tumours including 
prostate, loss of E-cadherin increases tumour cell 
motility and invasiveness and is associated with poor 
prognosis in cancer patients [39,52–54]. Similarly, 
examination of prostate cancer tissue samples using 
immunohistochemistry also revealed a reduction in the 
expression of cellular membrane E-cadherin that was 
concomitant with increasing Gleason score, clinical 
stage and a decline in survival [55]. In the clinical 
setting, plasma concentrations of E-cadherin are low in 
the later stage of prostate cancer patients and correlate 
with raised levels of PSA. In keeping with this, the use 
of plasma E-cadherin concentrations as a biomarker of 
the metastatic potential and to predict prognosis of 
prostate cancer has been proposed in clinical practice 
along with the use of PSA, particularly when aberrant 
modification of E-cadherin is likely to be involved in 
cancer invasion [53]. In addition to this, in vivo and in 
vitro studies have found that inhibition of N-cadherin 
using antibodies is able to delay the progression of 
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prostate cancer to castration resistance and also to 
inhibit the invasion and metastasis of castration-
resistant tumour growth suggesting the fundamental 
role of N-cadherin in promoting castration resistance 
and metastasis [56]. 
During cancer development, various extracellular 
signals could trigger the activation of EMT [57]. 
However, the full spectrum of critical mediators 
contributing to the activation of EMT remains uncertain. 
A few molecules capable of inducing EMT in many cell 
types have been identified including transforming 
growth factor-? (TGF-?), hepatocyte growth factor, 
platelet-derived growth factor, fibroblast growth factor, 
Wnt and Notch ligands, Hedgehog, epidermal growth 
factor (EGF) as well as the IGF family [57]. The action 
of these growth factors is thought to be cell type- or 
tissue type-specific and probably involves crosstalk 
between multiple pathways. Therefore combination of 
extracellular signals in the tumour microenvironment is 
needed to induce EMT [50]. The growth factors 
released by the cancer-associated stromal cells appear 
to trigger the functional activation of EMT-inducing 
transcription factors particularly zinc finger E-box 
binding homeobox 1(ZEB1), Slug, Snail, FOXC2, 
Goosecoid and Twist [48,57–62].  
Among all of the EMT-inducing growth factors, TGF-
? is undoubtedly a multifunctional cytokine that not only 
appears to be a primary inducer of EMT but also 
mediates critical cellular processes including apoptosis 
and immune responses [63]. During development, 
TGF-? is crucial for heart development [64], 
palatogenesis [65] as well as for testis development 
[66]: all are by virtue of its effect in regulating EMT. 
TGF-? signal via activation of Smad and non-smad 
signalling pathways including p38 MAP kinase (p38 
MAPK). Apart from TGF-?, p38 MAPK can also be 
activated by Ras and Wnt pathways, which cooperate 
with TGF-? to induce EMT. Many studies have shown 
that activation of the TGF-? pathway induces EMT and 
single cell migration in cancer cells. Its activation is 
also required for intravasation, extravasation and blood 
borne metastasis [67,68]. In prostate cancer, during the 
 
Figure 2: Epithelial-to-mesenchymal transition (EMT) during prostate cancer progression. 
During cancer progression, cancer cells undergo EMT to acquire a mesenchymal phenotype which is characterised with loss of 
cell polarity and increased migratory capacity and invasiveness. The acquisition of this mesenchymal phenotype facilitates the 
cancer cells to invade through the basement membrane and enter the circulatory system via intravasation into blood or lymph 
vessels. After arrival at the distant site, the cells facilitate extravasation and form micrometastases with the potential to 
proliferate into fully malignant, secondary tumours. Ultimately they undergo mesenchymal-to-epithelial transition (MET) to 
colonize distant organs thereby generating the final, life-threatening stage of cancer progression. 
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early stage of tumourigenesis, TGF-? acts as tumour 
suppressor by inhibiting cell proliferation and inducing 
apoptosis [69]. However, when the tumour progresses 
to clinically relevant disease, it becomes pro-oncogenic 
and switches its role to a promoter of EMT and 
metastasis, accelerating the pathologic malignant 
changes in the prostate [70]. TGF-beta also behaves in 
this manner during breast cancer progression and we 
have shown that both its pro- and anti-tumourigenic 
roles were at least partly mediated by IGFBP-3 [71]. 
The dual functions of TGF-? signalling on tumour 
initiation and progression are thought to be due to 
changes in the cell environment and consequent 
alterations in intracellular signalling. The tumour 
suppressive function of TGF-beta is mediated by a 
Smad-dependent pathway and inactivation of this 
pathway coupled with functional loss of TGF-? 
receptors is believed to activate its pro-oncogenic role. 
It has been suggested that TGF-? induces cancer cell 
invasive properties and dissemination from the primary 
tumour. However, when the cancer cells form 
micrometastasis at the distant organ, loss of TGF-? 
may stimulate an epithelial phenotype and colonization 
[21]. Intriguingly, it has also been shown that together 
with EGF, TGF-? may also promote prostate cancer 
progression by inducing immune suppression and 
promoting prostate cancer cell survival through the 
regulation of human leukocyte antigen class I antigens 
(HLA-I). TGF-? induces activation of Snail which leads 
to reduction in the transcription of nuclear factor 
kappa? (NF-?B) and subsequent loss in HLA-I protein 
levels. This in turn results in the attenuation of cytotoxic 
T cell-mediated lysis of and provides a survival effect in 
prostate cancer cells [72]. In addition, TGF-? can also 
promote bone metastasis in prostate cancer through 
regulating microRNA-96 (miR-96) in a Smad-
dependent transcription manner. Induced expression of 
miR-96 in response to TGF-? reduces its downstream 
target, AKT1S1. As the AKT1S1 protein is a negative 
regulator of mammalian target of rapamycin (mTOR), 
reduction in its expression enhances mTOR function 
thereby promoting an aggressive prostate cancer 
phenotype [73].  
As discussed earlier, EMT-inducing transcription 
factors particularly Snail, Slug, ZEB1 and Twist are 
activated during EMT by various growth factors 
particularly TGF-? [48,57-62]. A well-known EMT 
inducer, Snail transcription factor has been extensively 
studied in many cancers as well as in prostate cancer. 
This zinc finger transcription factor induced by TGF-? 
mediates the activation of EMT through repression of 
adhesion molecules particularly E-cadherin by binding 
to E-boxes in the proximal promoter region [61]. A 
number of studies have shown a strong correlation 
between Snail-mediated EMT with cell invasiveness 
and metastatic capacity. It has been shown that high 
expression of Snail is inversely correlated with E-
cadherin expression in tumour tissues and is 
associated with poor prognosis of patients suffering 
from cancer. Loss of E-cadherin is concomitant with 
activation of Wnt signalling hence increasing cell 
invasion and survival [74]. In prostate cancer, 
immunohistochemical studies using tissue microarray 
assessing the gene expression profiles of Snail, have 
discovered that the expression of Snail is positively 
correlated with Gleason grade, with the highest 
expression seen in metastatic prostate cancer [75,76]. 
This is also supported by a recent in vitro study 
showing higher Snail expression in PC3 cells which 
exhibit advanced cancer properties compared to 
androgen-dependent LNCaP cells which exhibit more 
epithelial properties [77]. The importance of Snail in 
EMT-associated cell migration has further been 
revealed by overexpression of Snail in LNCaP cells 
which resulted in relocalization of E-cadherin from the 
cell membrane to the cytosol and increases in vimentin 
[78]. Additionally, inhibition of Snail was also found to 
inhibit EMT in human androgen-independent prostate 
cells (AIPC) and inhibit cancer metastasis in mouse 
models [79]. Apart from inducing EMT-mediated 
migration, Snail is also found to promote prostate 
tumour proliferation by inducing a neuroendocrine 
phenotype in LNCaP cells [80], suggesting that multiple 
pathways are involved in inducing prostate cancer 
aggressiveness.  
Twist1, a basic Helix–Loop–Helix (bHLH) 
transcription factor, is initially found to regulate the 
expression of various target genes such as heparan 
sulfate 6-O-sulfotransferase 2 (HS6ST2), collagen, 
type I, alpha 1 (COL1A1) and coagulation factor II 
(thrombin) receptor (F2RL1) that are involved in cell 
differentiation, migration and survival. It is regarded as 
a proto-oncogene and its role in inducing EMT has 
been widely studied in many in vitro and in vivo 
models. Overexpression of TWIST1 induces EMT in 
breast, pancreatic and gastric cancers[81–83]. In 
prostate cancer, TWIST1 has been shown to induce 
EMT by increasing N-cadherin and fibronectin 
expression, promoting a more mesenchymal 
phenotype associated with increased prostate cancer 
cell migration and invasion [84,85].  
In addition to promoting invasion and metastasis, 
EMT also induces resistance to therapy. EMT has been 
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associated with resistance to chemotherapy in many 
cancers including epithelial ovarian [86], lung [87], 
breast [88] as well as prostate cancer [89,90]. In 
prostate cancer, Snail and ZEB1 transcription factors 
which are known to induce EMT, mediate resistance to 
the chemotherapeutic drugs cisplastin and docetaxel 
respectively [90,91].  
THE ROLE OF IGF SYSTEM IN PROSTATE 
CANCER  
The insulin-like growth factor (IGF) signalling axis is 
essential for normal development and maintenance of 
tissues including that of the prostate, and dysregulation 
of this pathway contributes to cancer progression and 
malignant transformation.  
Circulating plasma IGF-I is consistently found to be 
highly elevated in many cancer patients including 
breast [92], colorectal [93] and cervical cancer [94]. 
With prostate cancer, case control and prospective 
studies have reported associations of IGF-I with the 
risk and development of prostate cancer [95–98]. It has 
also been reported that higher levels of serum IGF-I 
with lower concentrations of IGFBP-3 are associated 
with prostate cancer mortality in men with advanced as 
opposed to localized prostate cancer, suggesting that 
IGF-I and IGFBP-3 may be potential biomarkers 
predicting death in men with advanced disease [99]. In 
vitro and in vivo studies have also contributed to our 
understanding of the IGF axis in the development of 
prostate cancer demonstrating that members of the 
IGF family are involved promoting a number of different 
processes involved in cancer development including 
growth, survival and migration (see review Biernacka 
2012) [100]. In this review we will focus on the roles of 
members of the IGF axis in promoting EMT.  
Alterations in insulin and IGFs, related to nutritional 
lifestyle and metabolic syndrome have been postulated 
to be important factors mediating the increased risk of 
prostate cancer [101]. Studies using dietary restriction 
(DR) in mice which is a classic experimental model to 
inhibit cancer development showed that DR was 
associated with a marked reduction in circulating IGF-I 
levels. The growth of chemically-induced liver tumours 
in mice was also inhibited by diet restriction and this 
was accompanied by a decrease in IGF-I 
concentrations [102]. Dietary restriction in mice has 
also been shown to increase apoptotic rates and 
reduce progression of bladder cancers, that was 
similarly associated with reduced levels of circulating 
IGF-I and in this study the positive impact of dietary 
restriction was inhibited when IGF-I levels were 
restored indicating a key role for IGF-I in mediating the 
effects of nutrition on tumour progression [103]. The 
increased expression of IGF-I by prostate cancer cells 
that have metastasized to bone suggests a role of  
IGF-I in specifically promoting osteoblastic metastases 
in prostate cancer patients [75]. 
Many studies have shown the link between 
metabolic syndrome and clinical cancers and growing 
evidence has shown the involvement of the IGF 
pathway in the mechanism that promotes tumour 
development in patients with metabolic syndrome 
[104]. It has been known for many years that the IGF 
pathway plays a central role in mediating the effects of 
nutrition on cell growth and metabolism [105] and so 
could be important in mediating cancer growth and 
survival in patients with a disturbed metabolism. It was 
suggested that chronic hyperinsulinaemia (commonly 
seen in metabolic syndrome) increases circulating IGF-
I by reducing gene expression and protein production 
of IGFBP-1 and IGFBP-2 in the liver, leading to 
activation of the IGF pathway which results in abnormal 
cellular proliferation and inhibition of apoptosis 
[23,104,106]. In vitro, it has also been reported that 
exposure of prostate cancer cells to 7mM glucose 
concentrations (and above), often seen in poorly 
controlled patients with type 2 diabetic induces 
chemoresistance which was associated with increased 
IGFBP-2 production [107]. Taken together, these 
reports suggest the involvement of the IGF axis in 
mediating the effect of altered metabolism on prostate 
cancer pathogenesis and metastatic progression.  
THE ROLE OF IGF SYSTEM IN MEDIATING EMT  
Aberrant stimulation of the IGF axis in prostate 
cancer cells is believed to contribute to the induction of 
EMT and subsequent progression of localised prostate 
cancer to metastatic disease. It has been widely known 
that IGF-I regulates the proliferation of prostate 
epithelial cells during growth and development. 
However, abnormal stimulation of IGF-IR by IGF-I has 
been found to induce spontaneous formation of 
neoplasia in prostate epithelium in BK5.IGF-I trans-
genic mice [108]. In addition, increased IGF-IR expres-
sion coupled with increase in IGF-I responsiveness has 
been implicated with the development of androgen 
independent progression with increased protection 
from apoptosis and enhanced mitotic activity [109].  
The two main signalling pathways downstream of 
the IGF-IR (PTEN/PI3K/Akt pathway and RAS/MAPK 
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pathway) are both involved in the EMT program by 
regulating the transcription factors twist, snail and 
ZEB1 [110]. One of the key features during EMT is loss 
of epithelial markers; ie E-cadherin and ?-catenin and 
increases in mesenchymal markers such as N-cadherin 
and fibronectin. IGF-I has been shown to promote 
epithelial prostate cancer cells to attain a more 
mesenchymal phenotype by regulating ZEB1 
expression [111]. ZEB1, a transcriptional repressor 
known to regulate EMT, mediates it action by down 
regulating E-cadherin expression through its binding 
with CANNTG sequence in the promoter region of E-
cadherin. Addition of exogenous IGF-I to human 
prostate cancer cell lines (ARCaP) induces up-
regulation of ZEB1 transcription and protein level in a 
MEK/ERK dependent manner [111]. Increased in ZEB1 
induces EMT, manifested by reduction in E-cadherin 
and ?-catenin and induction of mesenchymal markers 
N-cadherin, vimentin and fibronectin, thereby 
enhancing the ability of the cancer cells to migrate. 
Consistently, when ZEB1 is down-regulated through 
the use of siRNA, the epithelial phenotype of the 
cancer cells is restored as demonstrated by epithelial-
like changes in cell morphology and E-cadherin and ?-
catenin re-expression [111]. This finding is also 
consistent with other studies that showed a similar 
effect of IGF-I in inducing EMT-mediated invasion 
through regulating the ZEB1 expression in colorectal 
and breast cancer [112,113].  
The ability of IGF-I to induce EMT in many cancer 
cells including prostate is also dependent in its ability to 
increase the cellular level of ?-catenin, another 
epithelial marker in which its accumulation could lead 
to neoplastic transformation [114]. Apart from its role in 
cadherin-based cell adhesion, ?-catenin also 
participates in signal transduction through the Wnt 
signalling pathway, another important driver of EMT. As 
described earlier, activation of Wnt stabilises ?-catenin 
and induces its translocation from the cytoplasm to the 
nucleus where it associates with transcription factors 
from the TCF/ LEF family and promotes transcription of 
Wnt/? catenin target genes that promote cell survival, 
proliferation and invasion [44]. Increases in cellular 
levels of ?-catenin in androgen dependent and 
independent prostate cancer cells in response to IGF-I, 
either by increases in its phosphorylation or as a 
consequence of E-cadherin loss in the cell membrane 
could also lead to ?-catenin nuclear translocation and 
subsequent activation of TCF/LEF transcription factor 
family members [115–117]. IGF-I also increases cyclin 
D1, one of the target genes of the ?-catenin/TCF 
complex, and stimulates cell cycle transition leading to 
cancer cell proliferation [116]. Supporting these data is 
a study conducted using NBTII bladder carcinoma cells 
which showed that activation of the IGF pathway by 
IGF-II binding to the IGF-IR promoted EMT through the 
induction of intracellular sequestration and degradation 
of E-cadherin along with translocation of ?-catenin from 
the plasma membrane to the nucleus [118]. It has also 
been shown that IGF-I enhances the stability of ?-
catenin through glycogen synthase kinase-3? (GSK3?) 
inhibition [114]. GSK3?, an enzyme involved in the 
regulation of glycogen synthesis in response to insulin, 
is known to induce proteosomal targeting and 
degradation of ?-catenin by inducing its 
phosphorylation. It is also acts as a potent suppressor 
for EMT-inducer transcription factors, Snail and Slug 
[119,120]. Inhibition of GSK3? by IGF-I in prostate 
cancer can therefore regulate EMT and cancer 
metastasis by directly upregulating Snail and Slug 
expression. Taken together, these studies suggests an 
interplay between activation of IGF/IGF-IR and cell 
adhesion signalling as a crucial regulator in promoting 
EMT in prostate cancer cells by inducing atypical cell 
proliferation and tumour cell invasion. 
As mentioned previously IGFBPs are the main 
regulatory molecules of the IGFs: they bind with high 
affinity to IGF-I and IGF-II ligands in the circulation and 
modulate their availability and activity [121]. The IGF-
dependent and independent roles of IGFBPs in the 
development of cancers are well established and the in 
vitro and in vivo data have been extensively reviewed 
previously [37] . We will focus on the data indicating a 
role for IGFBPs in cancer progression and EMT: 
reduced levels of IGFBP-3 have been associated with 
cancer metastasis and increased survival in many 
cancers [122–125]. Similarly, prostate cancer patients 
with bone metastases have been reported to have 
significantly lower plasma levels of IGFBP-3 compared 
with clinically localised-prostate cancer patients, 
suggesting low levels of circulating IGFBP-3 are 
associated with reduced metastasis [126,127]. Low 
plasma IGFBP-3 coupled with increases in IGF-I have 
also been associated with all-cause prostate cancer 
mortality in men with clinically advanced disease as 
discussed previously [99]. An important role for the 
IGF-IR and IGFBP-3 in the homeostasis of prostate 
carcinoma cells has also been reported: inhibition of 
IGF-IR gene expression was shown to up-regulate 
IGFBP-3 which led to the inhibition of cell proliferation 
and invasion [128]. The anti-proliferative properties of 
IGFBP-3 in prostate cancer are also supported by a 
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study from Liu et al. that showed IGFBP-3 supressed 
tumor growth by inhibiting angiogenesis in an IGF-
independent way in CaP xenograft models [129]. In 
contrast to pro-apoptotic and anti-metastatic functions 
of IGFBP-3, there are a number of reports indicating 
the involvement of IGFBP-3 in promoting tumour 
progression. For example, immunohistochemistry 
studies have shown an increased level of IGFBP-3 in 
prostate adenocarcinoma compared with levels in 
benign tissue [130]. Evidence suggests that the 
response of a cancer cell to IGFBP3 is dependent on 
the cell environment, which may explain why both 
positive and negative effects of IGFBP-3 have been 
described for IGFBP-3 on prostate cancer progression. 
TGF-? is undoubtedly one of the most important 
inducers of EMT as we discussed earlier. TGF? can 
alter a cells environment in many ways, for example it 
enhances the production of extracellular matrix 
proteins, such as fibronectin [131] as part of its role in 
inducing EMT. TGF-beta is also one of the main 
regulators of IGFBP-3: activation of TGF-? has been 
found to up-regulate IGFBP-3 in cancer cells including 
those of the prostate [132] and a number of studies 
have shown functional interactions between the two 
(see review Huang SS 2005) [133] :it is likely therefore 
that IGFBP-3 will mediate some of the effects of TGF-
beta on EMT in prostate cancer.  
IGFBP-2, the second most abundant IGFBP in 
serum after IGFBP-3, also plays an important role in 
prostate cancer progression by stimulating prostate 
cancer cell proliferation in an IGF-dependent and 
independent manner. We have shown that IGFBP-2 
could promote prostate tumour progression by acting 
as a growth promoter and as a survival factor against 
docetaxel-induced cell death [134]. It has also been 
shown that IGFBP-2 plays an important role in 
promoting the metastatic ability of many cells including 
human dermal fibroblasts, breast cancer and glioma 
cells [33–35] through the interaction with ?-1 integrin 
receptors via the RGD sequence of IGFBP-2 [135]. 
This interaction leads to inactivation of phosphatase 
and tensin homolog (PTEN), a tumour suppressor gene 
and the phosphatase that normally restrains the 
PI3K/Akt pathway [136]. Inactivation of PTEN is 
associated with increases in the incidence and 
progression of prostate cancer in mouse models; a 
reduction in PTEN massively accelerated tumour 
growth, ultimately resulting in high-grade prostatic 
intraepithelial neoplasia and locally invasive carcinoma 
[137]. Immunohistochemistry studies have also 
reported higher levels of IGFBP-2 in malignant 
compared with benign prostatic epithelial cells 
[138,139]. A report describing LNCaP xenografts 
shows a significant increase in IGFBP-2 levels after 
androgen withdrawal as a result of an adaptive 
response to an androgen depleted environment that 
promotes IGF-I mediated cell survival and cancer 
progression [140].  
FUTURE PERSPECTIVES 
There is overwhelming evidence showing that a 
poor lifestyle is associated with progression of a 
number of different cancers including the prostate: 
currently obesity and associated type 2 diabetes 
represent one of today’s major health problems. 
Together this suggests that progression to metastatic 
disease will undoubtedly become more prevalent. The 
IGF axis clearly plays a number of important roles in 
effecting EMT and as IGFs are the major mediators of 
nutrition and metabolism, it will become even more 
important to gain a better understanding of these so 
that more effective interventions can be identified for 
prostate cancer patients that develop metastatic 
disease. A number of agents targeting the IGF-IR have 
already been developed and taken forward into clinical 
trials [141–143]. Despite promising preliminary data, 
the advanced clinical trials failed to show clinical 
benefit, which resulted in most drug companies ending 
current programs targeting the IGF-IR. These trials 
were undertaken on unselected patients: success of 
the drugs will be dependent upon the ability to identify 
which sub-set of patients will respond and this will 
require a greater understanding of the context; 
including an understanding of the effect of both the 
stage of progression of the cancer and the metabolic 
status of the host.  
ACKNOWLEDGEMENTS 
We would like to express our sincere thanks to 
Majlis Amanah Rakyat (MARA, Malaysia) and 
Universiti Kuala Lumpur Royal College of Medicine 
Perak for the research funding to support this work. We 
would also like to acknowledge the ‘Aiming to Beat 
Cancer Fund’, Bristol Oncology Centre, for supporting 
our work. 
REFERENCES 
[1] Cancer Facts & Figures 2015 - acspc-044552.pdf [Internet]. 
[cited 2015 Sep 9].Available from: http://www.cancer.org/acs/ 
groups/content/@editorial/documents/document/acspc-
044552.pdf 
[2] Prostate cancer statistics | Cancer Research UK [Internet]. 
[cited 2015 Sep 9]. Available from: http://www.cancer-
166    Journal of Analytical Oncology, 2015, Vol. 4, No. 4 Mansor et al. 
researchuk.org/health-professional/cancer-
statistics/statistics-by-cancer-type/prostate-cancer 
[3] Baade PD, Youlden DR, Cramb SM, . Epidemiology of 
prostate cancer in the Asia-Pacific region. Prostate Int 2013; 
1(2): 47-58.  
http://dx.doi.org/10.12954/PI.12014 
[4] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA 
Cancer J Clin 2015; 65(1): 5-29.  
http://dx.doi.org/10.3322/caac.21254 
[5] Steinberg GD, Carter BS, Beaty TH, et al. Family history and 
the risk of prostate cancer. Prostate 1990; 17(4): 337-47.  
http://dx.doi.org/10.1002/pros.2990170409 
[6] Stanford JL, Ostrander EA. Familial prostate cancer. 
Epidemiol Rev 2001; 23(1): 19-23.  
http://dx.doi.org/10.1093/oxfordjournals.epirev.a000789 
[7] Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. 
CA Cancer J Clin. 62(1): 10-29.  
http://dx.doi.org/10.3322/caac.20138 
[8] Allan CA, Collins VR, Frydenberg M, et al. Androgen 
deprivation therapy complications. Endocr Relat Cancer 
2014; 21(4): T119-29.  
http://dx.doi.org/10.1530/ERC-13-0467 
[9] Chen CD, Welsbie DS, Tran C, et al. Molecular determinants 
of resistance to antiandrogen therapy. Nat Med 2004; 10(1): 
33-9.  
http://dx.doi.org/10.1038/nm972 
[10] Nguyen-Nielsen M, Liede A, Maegbaek ML, et al. Survival 
and PSA-markers for mortality and metastasis in 
nonmetastatic prostate cancer treated with androgen 
deprivation therapy. Cancer Epidemiol. Elsevier; 2015; 39(4): 
623-32.  
http://dx.doi.org/10.1016/j.canep.2015.05.008 
[11] Taichman RS, Loberg RD, Mehra R, et al. The evolving 
biology and treatment of prostate cancer. J Clin Invest 2007; 
117(9): 2351-61.  
http://dx.doi.org/10.1172/JCI31791 
[12] Malik R, Khan AP, Asangani IA, et al. Targeting the MLL 
complex in castration-resistant prostate cancer. Nat Med 
2015; 21(4): 344-52.  
http://dx.doi.org/10.1038/nm.3830 
[13] Holly JMP, Zeng L, Perks CM. Epithelial cancers in the post-
genomic era: should we reconsider our lifestyle? Cancer 
Metastasis Rev 2013; 32(3-4): 673-705.  
http://dx.doi.org/10.1007/s10555-013-9445-5 
[14] Ito K. Prostate cancer in Asian men. Nat Rev Urol. Nature 
Publishing Group; 2014; 11(4): 197-212.  
[15] Key TJ, Schatzkin A, Willett WC, et al. Diet, nutrition and the 
prevention of cancer. Public Health Nutr 2007; 7(1a): 187-
200.  
[16] Zhang J-Q, Geng H, Ma M, et al. Metabolic Syndrome 
Components are Associated with Increased Prostate Cancer 
Risk. Med Sci Monit 2015; 21: 2387-96.  
http://dx.doi.org/10.12659/MSM.893442 
[17] Telli O, Sarici H, Ekici M, et al. Does metabolic syndrome or 
its components associate with prostate cancer when 
diagnosed on biopsy? Ther Adv Med Oncol 2015; 7(2): 63-7.  
http://dx.doi.org/10.1177/1758834014560158 
[18] Kasper JS, Giovannucci E. A meta-analysis of diabetes 
mellitus and the risk of prostate cancer. Cancer Epidemiol 
Biomarkers Prev 2006; 15(11): 2056-62.  
http://dx.doi.org/10.1158/1055-9965.EPI-06-0410 
[19] Liu X, Ji J, Sundquist K, et al. The impact of type 2 diabetes 
mellitus on cancer-specific survival: a follow-up study in 
Sweden. Cancer 2012; 118(5): 1353-61.  
http://dx.doi.org/10.1002/cncr.26420 
[20] Xiang Y, Xiong H, Cui Z, et al. The association between 
metabolic syndrome and the risk of prostate cancer, high-
grade prostate cancer, advanced prostate cancer, prostate 
cancer-specific mortality and biochemical recurrence. J Exp 
Clin Cancer Res 2013; 32: 9.  
http://dx.doi.org/10.1186/1756-9966-32-9 
[21] Bitting RL, Schaeffer D, Somarelli JA, et al. The role of 
epithelial plasticity in prostate cancer dissemination and 
treatment resistance. Cancer Metastasis Rev 2014; 33(2-3): 
441-68.  
http://dx.doi.org/10.1007/s10555-013-9483-z 
[22] Sara VR, Hall K. Insulin-like growth factors and their binding 
proteins. Physiol Rev 1990; 70(3): 591-614.  
[23] Jones JI, Clemmons DR. Insulin-like growth factors and their 
binding proteins: biological actions. Endocr Rev 1995; 16(1): 
3-34.  
[24] Clemmons DR, Underwood LE. Nutritional Regulation of IGF-
I and IGF Binding Proteins. Annu Rev Nutr 199; 11(1): 393-
412.  
[25] Salmon WD, Daughaday WH. A hormonally controlled serum 
factor which stimulates sulfate incorporation by cartilage in 
vitro. J Lab Clin Med 1957; 49(6): 825-36.  
[26] Ullrich A, Gray A, Tam AW, et al. Insulin-like growth factor I 
receptor primary structure: comparison with insulin receptor 
suggests structural determinants that define functional 
specificity. EMBO J 1986; 5(10): 2503-12.  
[27] LeRoith D, Werner H, Beitner-Johnson D, et al. Molecular 
and cellular aspects of the insulin-like growth factor I 
receptor. Endocr Rev 1995; 16(2): 143-63.  
http://dx.doi.org/10.1210/edrv-16-2-143 
[28] Baker J, Liu JP, Robertson EJ, et al. Role of insulin-like 
growth factors in embryonic and postnatal growth. Cell 1993; 
75(1): 73-82.  
http://dx.doi.org/10.1016/S0092-8674(05)80085-6 
[29] Yamaguchi Y, Flier JS, Benecke H, et al. Ligand-binding 
properties of the two isoforms of the human insulin receptor. 
Endocrinology 1993; 132(3): 1132-8.  
[30] Wang C-F, Zhang G, Zhao L-J, et al. Overexpression of the 
insulin receptor isoform A promotes endometrial carcinoma 
cell growth. PLoS One 2013; 8(8): e69001.  
http://dx.doi.org/10.1371/journal.pone.0069001 
[31] Belfiore A, Frasca F, Pandini G, et al. Insulin receptor 
isoforms and insulin receptor/insulin-like growth factor 
receptor hybrids in physiology and disease. Endocr Rev 
2009; 30(6): 586-623.  
http://dx.doi.org/10.1210/er.2008-0047 
[32] Kelley KM, Oh Y, Gargosky SE, et al. Insulin-like growth 
factor-binding proteins (IGFBPs) and their regulatory 
dynamics. Int J Biochem Cell Biol 1996; 28(6): 619-37.  
http://dx.doi.org/10.1016/1357-2725(96)00005-2 
[33] Lin MZ, Marzec KA, Martin JL, et al. The role of insulin-like 
growth factor binding protein-3 in the breast cancer cell 
response to DNA-damaging agents. Oncogene 2014; 33(1): 
85-96.  
http://dx.doi.org/10.1038/onc.2012.538 
[34] Terrien X, Bonvin E, Corroyer S, et al. Intracellular 
colocalization and interaction of IGF-binding protein-2 with 
the cyclin-dependent kinase inhibitor p21CIP1/WAF1 during 
growth inhibition. Biochem J 2005; 392(Pt 3): 457-65.  
http://dx.doi.org/10.1042/BJ20050517 
[35] Liu B, Lee HY, Weinzimer SA, et al. Direct functional 
interactions between insulin-like growth factor-binding 
protein-3 and retinoid X receptor-alpha regulate 
transcriptional signaling and apoptosis. J Biol Chem 2000; 
275(43): 33607-13.  
http://dx.doi.org/10.1074/jbc.M002547200 
[36] Perks CM, Holly JMP. IGF binding proteins (IGFBPs) and 
regulation of breast cancer biology. J Mammary Gland Biol 
Neoplasia 2008; 13(4): 455-69.  
http://dx.doi.org/10.1007/s10911-008-9106-4 
[37] Baxter RC. IGF binding proteins in cancer: mechanistic and 
clinical insights. Nat Rev Cancer. Nature Publishing Group, a 
The Role of the IGF Axis in Epithelial-to-Mesenchymal Transition Journal of Analytical Oncology, 2015, Vol. 4, No. 4     167 
division of Macmillan Publishers Limited. All Rights 
Reserved.; 2014; 14(5): 329-41.  
[38] Kalluri R, Neilson EG. Epithelial-mesenchymal transition and 
its implications for fibrosis. J Clin Invest 2003; 112(12): 1776-
84.  
http://dx.doi.org/10.1172/JCI200320530 
[39] Gravdal K, Halvorsen OJ, Haukaas SA, et al. A switch from 
E-cadherin to N-cadherin expression indicates epithelial to 
mesenchymal transition and is of strong and independent 
importance for the progress of prostate cancer. Clin Cancer 
Res 2007; 13(23): 7003-11.  
http://dx.doi.org/10.1158/1078-0432.CCR-07-1263 
[40] Murali AK, Norris JS. Differential expression of epithelial and 
mesenchymal proteins in a panel of prostate cancer cell 
lines. J Urol. Elsevier; 2012; 188(2): 632-8.  
[41] Al Saleh S, Al Mulla F, Luqmani YA. Estrogen receptor 
silencing induces epithelial to mesenchymal transition in 
human breast cancer cells. PLoS One 2011; 6(6): e20610.  
http://dx.doi.org/10.1371/journal.pone.0020610 
[42] Grant CM, Kyprianou N. Epithelial mesenchymal transition 
(EMT) in prostate growth and tumor progression. 
Translational Andrology and Urology 2013. p 202-11.  
[43] Polette M, Mestdagt M, Bindels S, et al. Beta-catenin and 
ZO-1: shuttle molecules involved in tumor invasion-
associated epithelial-mesenchymal transition processes. 
Cells Tissues Organs 2007; 185(1-3): 61-5.  
http://dx.doi.org/10.1159/000101304 
[44] Valenta T, Hausmann G, Basler K. The many faces and 
functions of ?-catenin. EMBO J. EMBO Press; 2012; 31(12): 
2714-36.  
http://dx.doi.org/10.1038/emboj.2012.150 
[45] Vega S, Morales A V, Ocaña OH, et al. Snail blocks the cell 
cycle and confers resistance to cell death. Genes Dev 2004; 
18(10): 1131-43.  
http://dx.doi.org/10.1101/gad.294104 
[46] Nisticò P, Bissell MJ, Radisky DC. Epithelial-mesenchymal 
transition: general principles and pathological relevance with 
special emphasis on the role of matrix metalloproteinases. 
Cold Spring Harb Perspect Biol 2012; 4(2).  
http://dx.doi.org/10.1101/cshperspect.a011908 
[47] Friedl P, Wolf K. Tumour-cell invasion and migration: 
diversity and escape mechanisms. Nat Rev Cancer 2003; 
3(5): 362-74.  
http://dx.doi.org/10.1038/nrc1075 
[48] Kalluri R, Weinberg RA. The basics of epithelial-
mesenchymal transition. J Clin Invest 2009; 119(6): 1420-8.  
http://dx.doi.org/10.1172/JCI39104 
[49] Thiery JP. Epithelial-mesenchymal transitions in tumour 
progression. Nat Rev Cancer 2002; 2(6): 442-54.  
http://dx.doi.org/10.1038/nrc822 
[50] Tsai JH, Yang J. Epithelial-mesenchymal plasticity in 
carcinoma metastasis. Genes Dev 2013; 27(20): 2192-206.  
http://dx.doi.org/10.1101/gad.225334.113 
[51] Zeisberg M, Neilson EG. Biomarkers for epithelial-mesen-
chymal transitions. J Clin Invest 2009; 119(6): 1429-37.  
http://dx.doi.org/10.1172/JCI36183 
[52] Christiansen JJ, Rajasekaran AK. Reassessing epithelial to 
mesenchymal transition as a prerequisite for carcinoma 
invasion and metastasis. Cancer Res 2006; 66(17): 8319-26.  
http://dx.doi.org/10.1158/0008-5472.CAN-06-0410 
[53] Bonaldi CM, Azzalis LA, Junqueira VBC, et al. Plasma levels 
of E-cadherin and MMP-13 in prostate cancer patients: 
correlation with PSA, testosterone and pathological 
parameters. Tumori; 101(2): 185-8.  
http://dx.doi.org/10.5301/tj.5000237 
[54] Kang Y, Massagué J. Epithelial-mesenchymal transitions: twist 
in development and metastasis. Cell 2004; 118(3): 277-9.  
http://dx.doi.org/10.1016/j.cell.2004.07.011 
[55] Whiteland H, Spencer-Harty S, Thomas DH, et al. Putative 
prognostic epithelial-to-mesenchymal transition biomarkers 
for aggressive prostate cancer. Exp Mol Pathol 2013; 95(2): 
220-6.  
http://dx.doi.org/10.1016/j.yexmp.2013.07.010 
[56] Tanaka H, Kono E, Tran CP, et al. Monoclonal antibody 
targeting of N-cadherin inhibits prostate cancer growth, 
metastasis and castration resistance. Nat Med 2010; 16(12): 
1414-20.  
http://dx.doi.org/10.1038/nm.2236 
[57] Moustakas A, Heldin C-H. Signaling networks guiding 
epithelial-mesenchymal transitions during embryogenesis 
and cancer progression. Cancer Sci 2007; 98(10): 1512-20.  
http://dx.doi.org/10.1111/j.1349-7006.2007.00550.x 
[58] Jechlinger M, Grünert S, Beug H. Mechanisms in epithelial 
plasticity and metastasis: insights from 3D cultures and 
expression profiling. J Mammary Gland Biol Neoplasia 2002; 
7(4): 415-32.  
http://dx.doi.org/10.1023/A:1024090116451 
[59] Shi Y, Massagué J. Mechanisms of TGF-beta signaling from 
cell membrane to the nucleus. Cell 2003; 113(6): 685-700.  
http://dx.doi.org/10.1016/S0092-8674(03)00432-X 
[60] Niessen K, Fu Y, Chang L, et al. Slug is a direct Notch target 
required for initiation of cardiac cushion cellularization. J Cell 
Biol 2008; 182(2): 315-25.  
http://dx.doi.org/10.1083/jcb.200710067 
[61] Medici D, Hay ED, Olsen BR. Snail and Slug promote 
epithelial-mesenchymal transition through beta-catenin-T-cell 
factor-4-dependent expression of transforming growth factor-
beta3. Mol Biol Cell 2008; 19(11): 4875-87.  
http://dx.doi.org/10.1091/mbc.E08-05-0506 
[62] Kokudo T, Suzuki Y, Yoshimatsu Y, et al. Snail is required for 
TGFbeta-induced endothelial-mesenchymal transition of 
embryonic stem cell-derived endothelial cells. J Cell Sci 
2008; 121(Pt 20): 3317-24.  
http://dx.doi.org/10.1242/jcs.028282 
[63] Massagué J. TGFbeta in Cancer. Cell 2008; 134(2): 215-30.  
http://dx.doi.org/10.1016/j.cell.2008.07.001 
[64] Sridurongrit S, Larsson J, Schwartz R, et al. Signaling via the 
Tgf-beta type I receptor Alk5 in heart development. Dev Biol 
2008; 322(1): 208-18.  
http://dx.doi.org/10.1016/j.ydbio.2008.07.038 
[65] Nawshad A, Medici D, Liu C-C, et al. TGFbeta3 inhibits E-
cadherin gene expression in palate medial-edge epithelial 
cells through a Smad2-Smad4-LEF1 transcription complex. J 
Cell Sci 2007; 120(Pt 9): 1646-53.  
http://dx.doi.org/10.1242/jcs.003129 
[66] Sarraj MA, Escalona RM, Umbers A, et al. Fetal testis 
dysgenesis and compromised Leydig cell function in Tgfbr3 
(beta glycan) knockout mice. Biol Reprod 2010 ; 82(1): 153-
62.  
http://dx.doi.org/10.1095/biolreprod.109.078766 
[67] Giampieri S, Manning C, Hooper S, et al. Localized and 
reversible TGFbeta signalling switches breast cancer cells 
from cohesive to single cell motility. Nat Cell Biol 2009; 
11(11): 1287-96.  
http://dx.doi.org/10.1038/ncb1973 
[68] Siegel PM, Shu W, Cardiff RD, et al. Transforming growth 
factor beta signaling impairs Neu-induced mammary 
tumorigenesis while promoting pulmonary metastasis. Proc 
Natl Acad Sci U S A 2003; 100(14): 8430-5.  
http://dx.doi.org/10.1073/pnas.0932636100 
[69] Pu H, Collazo J, Jones E, et al. Dysfunctional transforming 
growth factor-beta receptor II accelerates prostate 
tumorigenesis in the TRAMP mouse model. Cancer Res 
2009; 69(18): 7366-74.  
http://dx.doi.org/10.1158/0008-5472.CAN-09-0758 
[70] Yang F, Tuxhorn JA, Ressler SJ, et al. Stromal expression of 
connective tissue growth factor promotes angiogenesis and 
168    Journal of Analytical Oncology, 2015, Vol. 4, No. 4 Mansor et al. 
prostate cancer tumorigenesis. Cancer Res 2005; 65(19): 
8887-95.  
http://dx.doi.org/10.1158/0008-5472.CAN-05-1702 
[71] McCaig C, Fowler CA, Laurence NJ, et al. Differential 
interactions between IGFBP-3 and transforming growth 
factor-beta (TGF-beta) in normal vs cancerous breast 
epithelial cells. Br J Cancer 2002; 86(12): 1963-9.  
http://dx.doi.org/10.1038/sj.bjc.6600355 
[72] Chen X-H, Liu Z-C, Zhang G, et al. TGF-? and EGF induced 
HLA-I downregulation is associated with epithelial-
mesenchymal transition (EMT) through upregulation of snail 
in prostate cancer cells. Mol Immunol 2015; 65(1): 34-42.  
http://dx.doi.org/10.1016/j.molimm.2014.12.017 
[73] Siu MK, Tsai Y-C, Chang Y-S, et al. Transforming growth 
factor-? promotes prostate bone metastasis through 
induction of microRNA-96 and activation of the mTOR 
pathway. Oncogene 2015; 34(36): 4767-76.  
http://dx.doi.org/10.1038/onc.2014.414 
[74] Blanco MJ, Moreno-Bueno G, Sarrio D, et al. Correlation of 
Snail expression with histological grade and lymph node 
status in breast carcinomas. Oncogene 2002; 21(20): 3241-
6.  
http://dx.doi.org/10.1038/sj.onc.1205416 
[75] Dhanasekaran SM, Barrette TR, Ghosh D, et al. Delineation 
of prognostic biomarkers in prostate cancer. Nature 2001; 
412(6849): 822-6.  
http://dx.doi.org/10.1038/35090585 
[76] Beach S, Tang H, Park S, et al. Snail is a repressor of RKIP 
transcription in metastatic prostate cancer cells. Oncogene 
2008; 27(15): 2243-8.  
http://dx.doi.org/10.1038/sj.onc.1210860 
[77] Poblete CE, Fulla J, Gallardo M, et al. Increased SNAIL 
expression and low syndecan levels are associated with high 
Gleason grade in prostate cancer. Int J Oncol 2014; 44(3): 
647-54.  
[78] Odero-Marah VA, Wang R, Chu G, et al. Receptor activator 
of NF-kappaB Ligand (RANKL) expression is associated with 
epithelial to mesenchymal transition in human prostate 
cancer cells. Cell Res 2008; 18(8): 858-70.  
http://dx.doi.org/10.1038/cr.2008.84 
[79] Wen Y-C, Lee W-J, Tan P, et al. By inhibiting snail signaling 
and miR-23a-3p, osthole suppresses the EMT-mediated 
metastatic ability in prostate cancer. Oncotarget. Impact 
Journals; 2015. p. 21120-36.  
[80] McKeithen D, Graham T, Chung LWK, et al. Snail 
transcription factor regulates neuroendocrine differentiation 
in LNCaP prostate cancer cells. Prostate 2010; 70(9): 982-
92.  
http://dx.doi.org/10.1002/pros.21132 
[81] Yang J, Mani SA, Donaher JL, et al. Twist, a master regulator 
of morphogenesis, plays an essential role in tumor 
metastasis. Cell 2004; 117(7): 927-39.  
http://dx.doi.org/10.1016/j.cell.2004.06.006 
[82] Galván JA, Zlobec I, Wartenberg M, et al. Expression of E-
cadherin repressors SNAIL, ZEB1 and ZEB2 by tumour and 
stromal cells influences tumour-budding phenotype and 
suggests heterogeneity of stromal cells in pancreatic cancer. 
Br J Cancer 2015; 112(12): 1944-50.  
http://dx.doi.org/10.1038/bjc.2015.177 
[83] Liu A, Zhu Z-H, Chang S, et al. Twist expression associated 
with the epithelial-mesenchymal transition in gastric cancer. 
Mol Cell Biochem 2012; 367(1-2): 195-203.  
http://dx.doi.org/10.1007/s11010-012-1333-8 
[84] Alexander NR, Tran NL, Rekapally H, et al. N-cadherin gene 
expression in prostate carcinoma is modulated by integrin-
dependent nuclear translocation of Twist1. Cancer Res 2006; 
66(7): 3365-9.  
http://dx.doi.org/10.1158/0008-5472.CAN-05-3401 
[85] Shiota M, Zardan A, Takeuchi A, et al. Clusterin mediates 
TGF-?-induced epithelial-mesenchymal transition and 
metastasis via Twist1 in prostate cancer cells. Cancer Res 
2012; 72(20): 5261-72.  
http://dx.doi.org/10.1158/0008-5472.CAN-12-0254 
[86] Marchini S, Fruscio R, Clivio L, et al. Resistance to platinum-
based chemotherapy is associated with epithelial to 
mesenchymal transition in epithelial ovarian cancer. Eur J 
Cancer 2013; 49(2): 520-30.  
http://dx.doi.org/10.1016/j.ejca.2012.06.026 
[87] Witta SE. Restoring E-Cadherin Expression Increases 
Sensitivity to Epidermal Growth Factor Receptor Inhibitors in 
Lung Cancer Cell Lines. Cancer Res 2006; 66(2): 944-50.  
http://dx.doi.org/10.1158/0008-5472.CAN-05-1988 
[88] Holder AM, Akcakanat A, Adkins F, et al. Epithelial to 
mesenchymal transition is associated with rapamycin 
resistance. Oncotarget. Impact Journals; 2015. p 19500-13.  
[89] Pavese JM, Bergan RC. Circulating tumor cells exhibit a 
biologically aggressive cancer phenotype accompanied by 
selective resistance to chemotherapy. Cancer Lett 2014; 
352(2): 179-86.  
http://dx.doi.org/10.1016/j.canlet.2014.06.012 
[90] Marín-Aguilera M, Codony-Servat J, Reig Ò, et al. Epithelial-
to-mesenchymal transition mediates docetaxel resistance 
and high risk of relapse in prostate cancer. Mol Cancer Ther 
2014; 13(5): 1270-84.  
http://dx.doi.org/10.1158/1535-7163.MCT-13-0775 
[91] Baritaki S, Yeung K, Palladino M, et al. Pivotal roles of snail 
inhibition and RKIP induction by the proteasome inhibitor 
NPI-0052 in tumor cell chemoimmunosensitization. Cancer 
Res 2009; 69(21): 8376-85.  
http://dx.doi.org/10.1158/0008-5472.CAN-09-1069 
[92] Schernhammer ES, Holly JM, Pollak MN, et al. Circulating 
levels of insulin-like growth factors, their binding proteins, 
and breast cancer risk. Cancer Epidemiol Biomarkers Prev 
2005; 14(3): 699-704.  
http://dx.doi.org/10.1158/1055-9965.EPI-04-0561 
[93] Erarslan E, Co?kun Y, Türkay C, et al. IGF-I levels and 
visceral fat accumulation in colonic neoplasia. Clin Res 
Hepatol Gastroenterol 2014; 38(1): 99-105.  
http://dx.doi.org/10.1016/j.clinre.2013.06.004 
[94] Schaffer A, Koushik A, Trottier H, et al. Insulin-like growth 
factor-I and risk of high-grade cervical intraepithelial 
neoplasia. Cancer Epidemiol Biomarkers Prev 2007; 16(4): 
716-22.  
http://dx.doi.org/10.1158/1055-9965.EPI-06-0924 
[95] Cao Y, Nimptsch K, Shui IM, et al. Prediagnostic plasma 
IGFBP-1, IGF-1 and risk of prostate cancer. Int J Cancer 
2015; 136(10): 2418-26.  
http://dx.doi.org/10.1002/ijc.29295 
[96] Renehan AG, Zwahlen M, Minder C, et al. Insulin-like growth 
factor (IGF)-I, IGF binding protein-3, and cancer risk: 
systematic review and meta-regression analysis. Lancet 
(London, England) 2004; 363(9418): 1346-53.  
http://dx.doi.org/10.1016/S0140-6736(04)16044-3 
[97] Harman SM, Metter EJ, Blackman MR, et al. Serum levels of 
insulin-like growth factor I (IGF-I), IGF-II, IGF-binding protein-
3, and prostate-specific antigen as predictors of clinical pro-
state cancer. J Clin Endocrinol Metab 2000; 85(11): 4258-65.  
http://dx.doi.org/10.1210/jcem.85.11.6990 
[98] Chan JM, Stampfer MJ, Giovannucci E, et al. Plasma insulin-
like growth factor-I and prostate cancer risk: a prospective 
study. Science 1998; 279(5350): 563-6.  
http://dx.doi.org/10.1126/science.279.5350.563 
[99] Rowlands M-A, Holly JMP, Hamdy F, et al. Serum insulin-like 
growth factors and mortality in localised and advanced 
clinically detected prostate cancer. Cancer Causes Control 
2012; 23(2): 347-54.  
http://dx.doi.org/10.1007/s10552-011-9883-8 
The Role of the IGF Axis in Epithelial-to-Mesenchymal Transition Journal of Analytical Oncology, 2015, Vol. 4, No. 4     169 
[100] Biernacka KM, Perks CM, Holly JMP. Role of the IGF axis in 
prostate cancer. Minerva Endocrinol 2012; 37(2): 173-85.  
[101] Kaaks R. Nutrition, insulin, IGF-1 metabolism and cancer 
risk: a summary of epidemiological evidence. Novartis Found 
Symp 2004; 262: 247-60; discussion 260-8.  
http://dx.doi.org/10.1002/0470869976.ch16 
[102] Lagopoulos L, Sunahara GI, Würzner H, et al. The effects of 
alternating dietary restriction and ad libitum feeding of mice 
on the development of diethylnitrosamine-induced liver 
tumours and its correlation to insulinaemia. Carcinogenesis 
1991; 12(2): 311-5.  
http://dx.doi.org/10.1093/carcin/12.2.311 
[103] Dunn SE, Kari FW, French J, et al. Dietary restriction 
reduces insulin-like growth factor I levels, which modulates 
apoptosis, cell proliferation, and tumor progression in p53-
deficient mice. Cancer Res 1997; 57(21): 4667-72.  
[104] Mendonça FM, de Sousa FR, Barbosa AL, et al. Metabolic 
syndrome and risk of cancer: Which link? Metabolism 2015; 
64(2): 182-9.  
http://dx.doi.org/10.1016/j.metabol.2014.10.008 
[105] Narasimhan SD, Yen K, Tissenbaum HA. Converging 
pathways in lifespan regulation. Curr Biol 2009; 19(15): 
R657-66.  
http://dx.doi.org/10.1016/j.cub.2009.06.013 
[106] Aneke-Nash CS, Parrinello CM, Rajpathak SN, et al. 
Changes in insulin-like growth factor-I and its binding 
proteins are associated with diabetes mellitus in older adults. 
J Am Geriatr Soc 2015; 63(5): 902-9.  
http://dx.doi.org/10.1111/jgs.13390 
[107] Biernacka KM, Uzoh CC, Zeng L, et al. Hyperglycaemia-
induced chemoresistance of prostate cancer cells due to 
IGFBP2. Endocr Relat Cancer 2013; 20(5): 741-51.  
http://dx.doi.org/10.1530/ERC-13-0077 
[108] DiGiovanni J, Kiguchi K, Frijhoff A, et al. Deregulated 
expression of insulin-like growth factor 1 in prostate 
epithelium leads to neoplasia in transgenic mice. Proc Natl 
Acad Sci U S A 2000; 97(7): 3455-60.  
http://dx.doi.org/10.1073/pnas.97.7.3455 
[109] Krueckl SL, Sikes RA, Edlund NM, et al. Increased insulin-
like growth factor I receptor expression and signaling are 
components of androgen-independent progression in a 
lineage-derived prostate cancer progression model. Cancer 
Res 2004; 64(23): 8620-9.  
http://dx.doi.org/10.1158/0008-5472.CAN-04-2446 
[110] Malaguarnera R, Belfiore A. The emerging role of insulin and 
insulin-like growth factor signaling in cancer stem cells. Front 
Endocrinol (Lausanne) 2014; 5: 10.  
http://dx.doi.org/10.3389/fendo.2014.00010 
[111] Graham TR, Zhau HE, Odero-Marah VA, et al. Insulin-like 
growth factor-I-dependent up-regulation of ZEB1 drives 
epithelial-to-mesenchymal transition in human prostate 
cancer cells. Cancer Res 2008; 68(7): 2479-88.  
http://dx.doi.org/10.1158/0008-5472.CAN-07-2559 
[112] Spaderna S, Schmalhofer O, Hlubek F, et al. A transient, 
EMT-linked loss of basement membranes indicates 
metastasis and poor survival in colorectal cancer. 
Gastroenterology 2006; 131(3): 830-40.  
http://dx.doi.org/10.1053/j.gastro.2006.06.016 
[113] Lorenzatti G, Huang W, Pal A, et al. CCN6 (WISP3) 
decreases ZEB1-mediated EMT and invasion by attenuation 
of IGF-1 receptor signaling in breast cancer. J Cell Sci 2011; 
124(Pt 10): 1752-8.  
http://dx.doi.org/10.1242/jcs.084194 
[114] Verras M, Sun Z. Beta-catenin is involved in insulin-like 
growth factor 1-mediated transactivation of the androgen 
receptor. Mol Endocrinol 2005; 19(2): 391-8.  
http://dx.doi.org/10.1210/me.2004-0208 
[115] Playford MP, Bicknell D, Bodmer WF, et al. Insulin-like 
growth factor 1 regulates the location, stability, and 
transcriptional activity of beta-catenin. Proc Natl Acad Sci  
U S A 2000; 97(22): 12103-8.  
http://dx.doi.org/10.1073/pnas.210394297 
[116] Lee J, Ju J, Park S, et al. Inhibition of IGF-1 signaling by 
genistein: modulation of E-cadherin expression and 
downregulation of ?-catenin signaling in hormone refractory 
PC-3 prostate cancer cells. Nutr Cancer. Taylor & Francis 
Group; 2012; 64(1): 153-62.  
http://dx.doi.org/10.1080/01635581.2012.630161 
[117] Verras M, Sun Z. Beta-catenin is involved in insulin-like 
growth factor 1-mediated transactivation of the androgen 
receptor. Mol Endocrinol. Endocrine Society; 2005; 19(2): 
391-8.  
[118] Julien-Grille S, Moore R, Denat L, et al. The Role of Insulin-
like Growth Factors in the Epithelial to Mesenchymal 
Transition. Landes Bioscience; 2000.  
[119] Kao S-H, Wang W-L, Chen C-Y, et al. GSK3? controls 
epithelial-mesenchymal transition and tumor metastasis by 
CHIP-mediated degradation of Slug. Oncogene 2014; 
33(24): 3172-82.  
http://dx.doi.org/10.1038/onc.2013.279 
[120] Wang H, Wang H-S, Zhou B-H, et al. Epithelial-mesenchymal 
transition (EMT) induced by TNF-? requires AKT/GSK-3?-
mediated stabilization of snail in colorectal cancer. PLoS One 
2013; 8(2): e56664.  
http://dx.doi.org/10.1371/journal.pone.0056664 
[121] Jones JI, Clemmons DR. Insulin-like growth factors and their 
binding proteins: biological actions. Endocr Rev. Endocrine 
Society; 1995; 16(1): 3-34.  
[122] Gill ZP, Perks CM, Newcomb P V, et al. Insulin-like growth 
factor-binding protein (IGFBP-3) predisposes breast cancer 
cells to programmed cell death in a non-IGF-dependent 
manner. J Biol Chem 1997; 272(41): 25602-7.  
http://dx.doi.org/10.1074/jbc.272.41.25602 
[123] Naspi A, Panasiti V, Abbate F, et al. Insulin-like-growth-
factor-binding-protein-3 (IGFBP-3) contrasts melanoma 
progression in vitro and in viov. PLoS One 2014; 9(6): 
e98641.  
http://dx.doi.org/10.1371/journal.pone.0098641 
[124] Natsuizaka M, Kinugasa H, Kagawa S, et al. IGFBP3 
promotes esophageal cancer growth by suppressing 
oxidative stress in hypoxic tumor microenvironment. Am J 
Cancer Res 2014; 4(1): 29-41.  
[125] Xue M, Fang Y, Sun G, et al. IGFBP3, a transcriptional target 
of homeobox D10, is correlated with the prognosis of gastric 
cancer. PLoS One 2013; 8(12): e81423.  
http://dx.doi.org/10.1371/journal.pone.0081423 
[126] Shariat SF, Lamb DJ, Kattan MW, et al. Association of 
preoperative plasma levels of insulin-like growth factor I and 
insulin-like growth factor binding proteins-2 and -3 with 
prostate cancer invasion, progression, and metastasis. J Clin 
Oncol 2002; 20(3): 833-41.  
http://dx.doi.org/10.1200/JCO.20.3.833 
[127] Terracciano D, Bruzzese D, Ferro M, et al. Preoperative 
insulin-like growth factor-binding protein-3 (IGFBP-3) blood 
level predicts gleason sum upgrading. Prostate 2012; 72(1): 
100-7.  
http://dx.doi.org/10.1002/pros.21411 
[128] Grzmil M, Hemmerlein B, Thelen P, et al. Blockade of the 
type I IGF receptor expression in human prostate cancer 
cells inhibits proliferation and invasion, up-regulates IGF 
binding protein-3, and suppresses MMP-2 expression. J 
Pathol 2004; 202(1): 50-9.  
http://dx.doi.org/10.1002/path.1492 
[129] Liu B, Lee K-W, Anzo M, et al. Insulin-like growth factor-
binding protein-3 inhibition of prostate cancer growth involves 
suppression of angiogenesis. Oncogene 2007; 26(12): 1811-
9.  
http://dx.doi.org/10.1038/sj.onc.1209977 
170    Journal of Analytical Oncology, 2015, Vol. 4, No. 4 Mansor et al. 
[130] Massoner P, Haag P, Seifarth C, et al. Insulin-like growth 
factor binding protein-3 (IGFBP-3) in the prostate and in 
prostate cancer: local production, distribution and secretion 
pattern indicate a role in stromal-epithelial interaction. 
Prostate 2008; 68(11): 1165-78.  
http://dx.doi.org/10.1002/pros.20785 
[131] Reiss M. Transforming growth factor-beta and cancer: a love-
hate relationship? Oncol Res 1997; 9(9): 447-57.  
[132] Hwa V, Oh Y, Rosenfeld RG. Insulin-like growth factor 
binding protein-3 and -5 are regulated by transforming 
growth factor-beta and retinoic acid in the human prostate 
adenocarcinoma cell line PC-3. Endocrine 1997; 6(3): 235-
42.  
http://dx.doi.org/10.1007/BF02820498 
[133] Huang SS, Huang JS. TGF-? control of cell proliferation. J 
Cell Biochem 2005; 96(3): 447-62.  
http://dx.doi.org/10.1002/jcb.20558 
[134] Uzoh CC, Holly JMP, Biernacka KM, et al. Insulin-like growth 
factor-binding protein-2 promotes prostate cancer cell growth 
via IGF-dependent or -independent mechanisms and 
reduces the efficacy of docetaxel. Br J Cancer 2011; 
104(10): 1587-93.  
http://dx.doi.org/10.1038/bjc.2011.127 
[135] Han S, Li Z, Master LM, et al. Exogenous IGFBP-2 promotes 
proliferation, invasion, and chemoresistance to temozolomide 
in glioma cells via the integrin ?1-ERK pathway. Br J Cancer 
2014; 111(7): 1400-9.  
http://dx.doi.org/10.1038/bjc.2014.435 
[136] Perks CM, Vernon EG, Rosendahl AH, et al. IGF-II and 
IGFBP-2 differentially regulate PTEN in human breast cancer 
cells. Oncogene 2007; 26(40): 5966-72.  
http://dx.doi.org/10.1038/sj.onc.1210397 
[137] Trotman LC, Niki M, Dotan ZA, et al. Pten dose dictates 
cancer progression in the prostate. PLoS Biol 2003; 1(3): 
E59.  
http://dx.doi.org/10.1371/journal.pbio.0000059 
[138] Cohen P, Peehl DM, Stamey TA, et al. Elevated levels of 
insulin-like growth factor-binding protein-2 in the serum of 
prostate cancer patients. J Clin Endocrinol Metab 1993; 
76(4): 1031-5.  
[139] Tennant MK, Thrasher JB, Twomey PA, et al. Insulin-like 
growth factor-binding protein-2 and -3 expression in benign 
human prostate epithelium, prostate intraepithelial neoplasia, 
and adenocarcinoma of the prostate. J Clin Endocrinol Metab 
1996; 81(1): 411-20.  
[140] Kiyama S, Morrison K, Zellweger T, et al. Castration-induced 
increases in insulin-like growth factor-binding protein 2 
promotes proliferation of androgen-independent human 
prostate LNCaP tumors. Cancer Res 2003; 63(13): 3575-84.  
[141] Boone DN, Lee A V. Targeting the insulin-like growth factor 
receptor: developing biomarkers from gene expression 
profiling. Crit Rev Oncog 2012; 17(2): 161-73.  
http://dx.doi.org/10.1615/CritRevOncog.v17.i2.30 
[142] Lee A V, Yee D. Targeting IGF-1R: at a crossroad. Oncology 
(Williston Park) 2011; 25(6): 535-6; discussion 551.  
[143] Chen HX, Sharon E. IGF-1R as an anti-cancer target--trials 
and tribulations. Chin J Cancer 2013; 32(5): 242-52.  
http://dx.doi.org/10.5732/cjc.012.10263 
 
 
 
 
 
Received on 30-09-2015 Accepted on 19-10-2015 Published on 11-12-2015 
 
http://dx.doi.org/10.6000/1927-7229.2015.04.04.5 
 
© 2015 Mansor et al.; Licensee Lifescience Global. 
This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License 
(http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted, non-commercial use, distribution and reproduction in 
any medium, provided the work is properly cited. 
 
